Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. (Registrant) on March 16, 2017, covering events occurring in March 2017. The Registrant is a foreign private issuer headquartered in Kfar Saba, Israel. The filing reports on a significant legal development regarding corporate governance and capital structure.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a court order and proposed corporate actions.
Material Changes and Corporate Actions
On March 14, 2017, the District Court of Tel Aviv granted the Registrant's request to convene two Special General Meetings:
- Shareholder Meeting: To approve (i) extending the expiration date of Series-1 Stock Options to 80 days from court approval (previously extended to June 30, 2017), (ii) amending the exercise price of Series-1 Stock Options from NIS 1.85 to NIS 1.20, and (iii) the proposed delisting of ordinary shares from the Tel Aviv Stock Exchange.
- Option Holder Meeting: To approve (i) extending the expiration date of Series-1 Stock Options and (ii) amending the exercise price from NIS 1.85 to NIS 1.20.
Outlook, Risks, and Management Commentary
Management intends to act promptly to convene the required Special General Meetings. The proposed reduction in the exercise price of stock options and the potential delisting from the Tel Aviv Stock Exchange represent significant structural changes that require shareholder and option holder approval. The filing does not provide specific forward-looking financial guidance or discuss operational risks beyond the immediate need for these approvals.
Key Facts for Investor Verification
- Verify the outcome of the Special General Meetings regarding the extension of Series-1 Stock Options and the reduction of the exercise price to NIS 1.20.
- Confirm the status and timeline of the proposed delisting from the Tel Aviv Stock Exchange.
- Review the impact of the stock option price amendment on potential dilution and employee compensation costs.
- Check for subsequent filings detailing the results of the shareholder and option holder votes.